ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma
Ontology highlight
ABSTRACT: Proteomic study studying how ARID1A-mediated transcriptional rewiring drives resistance to MAPK inhibitors in melanoma by altering signalling pathways, immune interactions, and receptor dynamics, highlighting potential targets for combinatorial therapies.
INSTRUMENT(S): Orbitrap Exploris 480
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Melanocyte, Skin
DISEASE(S): Skin Melanoma
SUBMITTER: Evangelia Petsalaki
LAB HEAD: Evangelia Petsalaki
PROVIDER: PXD058857 | Pride | 2025-01-14
REPOSITORIES: pride
ACCESS DATA